Peanut Allergy Treatment Palforzia Is One Step Closer to Market
A new biologic drug to treat a peanut allergy has received a vote of support from an advisory committee of the Food and Drug Administration (FDA).
The therapy is designed to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental peanut exposure in children age 4 through 17 who have a confirmed diagnosis of a peanut allergy.
The application for approval is currently under review by the FDA, with a review action date of late January 2020.
The FDA has shown support for a therapy that could save lives and ease anxiety for millions of families.
Read full article ↗